Abstract
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new emerging coronavirus that causes coronavirus disease 2019 (COVID-19). Whole-genome tracking of the SARS-CoV-2 enhanced our understanding of the mechanism of disease, control, and prevent COVID-19 infections.
Materials and Methods In the current study, we investigated 1221 SARS-CoV-2 protein sequences of Iranian SARS-CoV-2 in the public database of the GISAID from January 2019 to April 2022. Prepare a list of suitable samples and preprocess performed by python programming language. To compare and identify mutation patterns SARS-CoV-2 genome was aligned to the Wuhan-Hu-1 as a reference sequence.
Results Our investigation revealed that spike-P323L, ORF9c-G50N, NSP14-I42V, spike-D614G, NSP4-T492I, nucleocapsid-R203K, nucleocapsid-G204R, membrane-A63T, membrane-Q19E, NSP5-P132H, envelope-T9I, NSP3-G489S, ORF3a-T24I, membrane-D3G, spike-S477N, Spike-D478K, nucleocapsid-S235F, spike-N501Y, nucleocapsid-D3L, and spike-P861H as the most frequent mutations among the Iranian SARS-COV-2 sequences. Furthermore, it was observed that more than 95 % of the SARS-CoV-2 genome, including NSP7, NSP8, NSP9, NSP10, NSP11, and ORF8, had no mutation when compared to the Wuhan-Hu-1. Finally, our data indicated the ORF3a-T24I, NSP3-G489S, NSP5-P132H, NSP14-I42V, envelope-T9I, nucleocapsid-D3L, membrane-Q19E, and membrane-A63T mutations might be one of the responsible factors for the surge in the SARS-CoV-2 omicron variant wave in Iran.
Discussion Our results highlight the value of real-time genomic surveillance that help to identify novel SARS-CoV-2 variants and could be applied to update SARS-CoV-2 diagnostic tools, vaccine design, and understanding of the mechanisms of adaptation to a new host environment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
AASs of Genome sequences of SARS-CoV-2 samples were retrieved from the GISAID database (https://www.gisaid.org/) for different geographic locations in Iran. We have access to this database with Erasmus Medical Center's permission.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Author list updated
Data Availability
All data produced in the present study are available upon reasonable request to the authors
